Trial Profile
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Metformin; Sodium-glucose transporter 2 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LIRA-ADD2SGLT2i
- Sponsors Novo Nordisk
- 01 Oct 2021 Results of post- hoc analysis assessing whether baseline characteristics influenced these findings published in the Diabetes, Obesity and Metabolism
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 08 Aug 2018 Primary endpoint has been met. (Change in HbA1c)